Zobrazeno 1 - 3
of 3
pro vyhledávání: '"GAETANO eFACCHINI"'
Autor:
GAETANO eFACCHINI, Chiara eDella Pepa, Carla eCavaliere, Sabrina Chiara Cecere, Marilena eDi Napoli, Carmine eD'Aniello, Anna eCrispo, Gelsomina eIovane, Piera eMaiolino, Teresa eTramontano, Raffaele ePiscitelli, Salvatore ePisconti, Lino eDel Pup, Maurizio eMontella, Massimiliano eBerretta, Domenico eSorrentino, Sisto ePerdonà, Sandro ePignata
Publikováno v:
Frontiers in Pharmacology, Vol 7 (2016)
BACKGROUND: the efficacy of Vinflunine, after failure of platinum-based chemotherapy in patients with metastatic or recurrent Transitional Cell Cancer of the Urothelial Tract, TCCU, has been demonstrated in an international, randomized, phase III tri
Externí odkaz:
https://doaj.org/article/78628b1d212d42b592433eb875f4d941
Autor:
Gaetano eFacchini, Orazio eCaffo, Cinzia eOrtega, Carmine eD'Aniello, Marilena eDi Napoli, Sabrina Chiara Cecere, Chiara eDella Pepa, Anna eCrispo, Francesca eMaines, Fiorella eRuatta, Gelsomina eIovane, Salvatore ePisconti, Maurizio eMontella, Massimiliano eBerretta, Sandro ePignata, Carla eCavaliere
Publikováno v:
Frontiers in Pharmacology, Vol 7 (2016)
BACKGROUND Abiraterone Acetate (AA) is approved for the treatment of mCRPC after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated and for treatment of mCRPC progressed during or after docetaxel-based chemot
Externí odkaz:
https://doaj.org/article/9e52a552ee434e6d8492083d029b6790
Autor:
GAETANO eFACCHINI, Chiara eDella Pepa, Carla eCavaliere, Sabrina Chiara Cecere, Marilena eDi Napoli, Carmine eD'Aniello, Anna eCrispo, Gelsomina eIovane, Piera eMaiolino, Teresa eTramontano, Raffaele ePiscitelli, Salvatore ePisconti, Lino eDel Pup, Maurizio eMontella, Massimiliano eBerretta, Domenico eSorrentino, Sisto ePerdonà, Sandro ePignata
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 7 (2016)
Frontiers in Pharmacology, Vol 7 (2016)
Background: The efficacy of Vinflunine, after failure of platinum-based chemotherapy in patients with metastatic or recurrent Transitional Cell Cancer of the Urothelial Tract, TCCU, has been demonstrated in an international, randomized, phase III tri